Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,135.37
(
-0.05%
)
US TECH 100
26,349.20
(
0.18%
)
Dow Jones
48,941.63
(
-0.41%
)
Brent Oil
109.22
(
4.60%
)
Bitcoin
76,659.53
(
0.41%
)
News Focus
News Focus
Post# of 347009
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Protector

Send PM Follow Ignore
Followers 140
Posts 11663
Boards Moderated 0
Alias Born 03/15/2011

Protector

Re: ku post# 280009

Thursday, 12/01/2016 11:26:30 AM

Thursday, December 01, 2016 11:26:30 AM

Post# of 347009
ku, no, the approval of a first 3rd line treatment for NSCLC DURING Sunrise blew it.

If the patients in the CTRL arm would have evented because after progression they didn't have any next treatment anymore then (and frankly for the patients I am happy they did have a next treatment available) then bavituximab would not only have proven again that it worked but Sunrise would not have stopped early. Nothing Garnick could do unless one wants to claim to know the outcome of Opdivo trials UP-FRONT of course.

Peregrine Pharmaceuticals the Microsoft of Biotechnology! All In My Opinion. I am not advising anything, nor accusing anyone.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote